Qingsong Liu

Affiliations: 
Chinese Academic Science, High Magnetic Field Laboratory 
Area:
Translation medicine
Google:
"Qingsong Liu"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Chen N, Qi Y, Ma X, et al. (2022) Rediscovery of Traditional Plant Medicine: An Underestimated Anticancer Drug of Chelerythrine. Frontiers in Pharmacology. 13: 906301
Liu J, Gao J, Wang A, et al. (2022) Nintedanib overcomes drug resistance from upregulation of FGFR signaling and imatinib-induced KIT mutations in gastrointestinal stromal tumors. Molecular Oncology
Yang J, Weisberg EL, Qi S, et al. (2022) Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia
Zhou B, Liang X, Mei H, et al. (2021) Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. Journal of Medicinal Chemistry
Lu T, Cao J, Zou F, et al. (2021) Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). European Journal of Pharmacology. 173944
Li F, Liang X, Jiang Z, et al. (2020) Discovery of ()-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1-pyrazolo[3,4-]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. Journal of Medicinal Chemistry
Ye Z, Wang Y, Wu H, et al. (2020) Chemoproteomic profiling of an Ibrutinib analogue reveals its unexpected role in DNA damage repair. Chembiochem : a European Journal of Chemical Biology
Wang B, Zhang W, Liu X, et al. (2020) Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. European Journal of Medicinal Chemistry. 207: 112744
Liu J, Liang Q, Wang A, et al. (2020) Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy. 5: 200
Weisberg E, Parent A, Yang PL, et al. (2020) Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research. 37: 167
See more...